Population pharmacokinetics of NNZ‐2566 in healthy subjects
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ejps.2017.05.032
Abstract: Abstract NNZ‐2566 is a novel, small molecule being developed as a treatment for cognitive impairment in different CNS conditions, including Rett and Fragile‐X syndrome, both of which are associated with moderate to severe neurodevelopmental disorder.… read more here.
Keywords: volume distribution; pharmacokinetics nnz; population pharmacokinetics; healthy subjects ... See more keywords